Extending the footprint record of Pareiasauromorpha to the Cisuralian : earlier appearance and wider palaeobiogeography of the group

Pareiasauromorpha is one of the most important tetrapod groups of the Permian. Skeletal evidence suggests a late Kungurian origin in North America, whereas the majority of occurrences come from the Guadalupian and Lopingian of South Africa and Russia. However, Pareiasauromorpha footprints include the ichnogenus Pachypes, which is unknown from strata older than late Guadalupian. A revision of several Pachypes-like footprints from the Cisuralian-Guadalupian of Europe and North America confirm the occurrence of this ichnogenus and of the ichnospecies Pachypes ollieri comb. nov. beginning in the Artinskian. This is the earliest known occurrence of Pachypes and it coincides with the Artinskian reptile radiation. Based on a synapomorphy-based track-trackmaker correlation, P. ollieri can be attributed to nycteroleter pareiasauromorphs such as Macroleter. Therefore, the earliest occurrences of pareiasauromorph footprints precede by at least 10 myr the earliest occurrence of this group in the skeletal record. Moreover, the palaeobiogeography of the group is extended to the Cisuralian and Guadalupian of western Europe

No association between fear of hypoglycemia and blood glucose variability in type 1 diabetes: The cross-sectional VARDIA study

AIMS: In type 1 diabetes (T1D), treatment efficacy is limited by the unpredictability of blood glucose results and glycemic variability (GV). Fear of Hypoglycemia (FOH) remains a major brake for insulin treatment optimization. We aimed to assess the association of GV with FOH in participants with T1D in an observational cross-sectional study performed in 9 French Diabetes Centres (NCT02790060). METHODS: Participants were T1D for ≥5 years, aged 18-75 years, on stable insulin therapy for ≥3 months. The coefficient of variation (CV) of blood glucose and mean amplitude of glycemic excursions (MAGE) were used to assess GV from 7-point self-monitoring of blood glucose (SMBG). FOH was assessed using the validated French version of the Hypoglycemia Fear Survey-II (HFS-II) questionnaire. RESULTS: Among a total of 570 recruited participants, 298 were suitable for analysis: 46% women, 58% on continuous subcutaneous insulin infusion [CSII], mean age 49 ± 16 years, HbA1c 7.5 ± 0.9%, HFS-II score 67 ± 18 and 12% with recent history of severe hypoglycemia during the previous 6 months, mean CV 39.8 ± 9.7% and MAGE 119 ± 42 mg/dL. CV and MAGE did not significantly correlate with HFS-II score (R = -0.05;P = 0.457 and R = 0.08;P = 0.170). Participants with severe hypoglycemia in the previous 6 months had higher HFS scores. Participants with higher HFS scores presented more hypoglycemias during follow-up. CONCLUSIONS: FOH as determined using the HFS-II questionnaire was not associated with 7-point SMBG variability in participants with T1D, but was associated with a positive history of severe hypoglycemia. Higher FOH was associated with higher frequency of hypoglycemia during follow-up